Close Menu

NEW YORK (GenomeWeb) – PerkinElmer said after the close of the market on Wednesday that its third quarter revenues grew 22 percent year over year, paced by its diagnostics segment, which was up 59 percent.

For the three months ended Sept. 30, the company reported total revenues of $674.3 million, up from $554.3 million a year ago, but short of the consensus Wall Street estimate of $676.4 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.